WO2023187612 - METHOD OF TREATING CHRONIC HEPATITIS B
National phase entry:
Publication Number
WO/2023/187612
Publication Date
05.10.2023
International Application No.
PCT/IB2023/053022
International Filing Date
27.03.2023
Title **
[English]
METHOD OF TREATING CHRONIC HEPATITIS B
[French]
MÉTHODE DE TRAITEMENT DE L'HÉPATITE B CHRONIQUE
Applicants **
GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
Inventors
CREMER, Ji Won
LIM, Jessica Watson
MAGEE, Mindy
NADER, Ahmed
QUINN, Geoffry David
THEODORE, Dickens
YOUSSEF, Amir
Priority Data
63/324,662
29.03.2022
US
63/365,535
31.05.2022
US
63/374,393
02.09.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2531 | |
| EPO | Filing, Examination, Granting | 11317 | |
| Japan | Filing, Examination, Granting | 2296 | |
| South Korea | Filing, Examination, Granting | 2347 | |
| USA | Filing, Examination, Granting | 6540 |
Total:
25,031
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present disclosure is related to methods for treating chronic hepatitis B. The methods comprise administering to a subject in need thereof a therapeutically effective amount of bepirovirsen, wherein the subject has a HBsAg baseline level of not greater than a threshold level.[French]
La présente invention concerne des méthodes de traitement de l'hépatite B chronique qui consistent à administrer à un sujet qui en a besoin une quantité thérapeutiquement efficace de bépirovirsen, le sujet ayant un niveau de base HBsAg non supérieur à un niveau seuil.